Pacira Pharmaceuticals (PCRX) PT Lowered to $39 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Truist Securities Double Downgrades Pacira Pharmaceuticals (PCRX) to Sell
August 13, 2024 6:06 AM EDTTruist Securities analyst Les Sulewski downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Sell with a price target of $8.00 (from $30.00).
The analyst comments "We revisit our core thesis on PCRX after our follow-up call with KOL conveys generic Exparel launch is... More
